Allogene Therapeutics, Inc. (ALLO) Cash Flow Statement
Allogene Therapeutics, Inc. (ALLO) generated -$102.2M of operating cash flow over the twelve months to 2026-06-30, spent $13.3M on capital expenditure and had free cash flow of -$115.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALLOAllogene Therapeutics, Inc.Follow ALLO — free
—
Price chart with a free account
- Market cap
- 431.9M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.18 | -0.22 | -0.24 | -0.20 | -0.15 | -0.10 | |
| Capital expenditure | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | -0.01 | |
| Free cash flow | -0.21 | -0.24 | -0.25 | -0.21 | -0.16 | -0.12 | |
| Stock-based compensation | 0.08 | 0.08 | 0.07 | 0.05 | 0.04 | — |
USD billions · SEC XBRL
Allogene Therapeutics, Inc. — questions
- What is Allogene Therapeutics, Inc.'s operating cash flow?
- -$102.2M over the twelve months to 2026-06-30.
- How much does Allogene Therapeutics, Inc. spend on capital expenditure?
- $13.3M over the twelve months to 2026-06-30.
- What is Allogene Therapeutics, Inc.'s free cash flow?
- -$115.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Allogene Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.